Welcome to our dedicated page for Cypherpunk Technologies news (Ticker: CYPH), a resource for investors and traders seeking the latest updates and insights on Cypherpunk Technologies stock.
Cypherpunk Technologies Inc. reports developments tied to its privacy technology strategy, including a digital asset treasury anchored by Zcash (ZEC), investments in privacy-focused technology, and updates on Zcash-related holdings and network exposure. The company was formerly Leap Therapeutics and now combines its ZEC treasury activity with participation in the broader privacy technology ecosystem.
Company news also covers financial results, governance and advisor appointments, and the continuing biopharma work of its Leap Therapeutics subsidiary. That subsidiary is developing cancer therapy candidates including sirexatamab (DKN-01), a monoclonal antibody targeting DKK1, and the preclinical antibody program FL-501 for cachexia-related indications.
Cypherpunk Technologies (Nasdaq:CYPH) launched Cypherpunk Mining, which it states is now the world's largest Zcash mining fleet, following a $33.33 million equity-based transaction with Winklevoss Capital affiliates. Cypherpunk Mining acquired Z15 Pro machines totaling approximately 4.2 GSol/s of Equihash hashrate, currently about 18% of the Zcash network and deployed across U.S. facilities.
According to Cypherpunk, the deal was paid via a pre-funded warrant for 43,290,042 CYPH shares at an exercise price of $0.001 per share, implying a purchase price of $0.77 per share. The company holds 323,394.38 ZEC, roughly 1.92% of circulating supply, and targets 5%. Industry veteran Kevin Zhang joins as Head of Mining.
Cypherpunk Technologies (Nasdaq: CYPH) reported second quarter 2026 net income of $39.4 million, or $0.18 diluted EPS, versus a net loss of $16.6 million a year earlier. The swing was primarily driven by a $46.0 million unrealized gain from marking its Zcash (ZEC) treasury to market as ZEC rose from $243.35 to $400.09.
As of August 11, 2026, Cypherpunk held 323,394.38 ZEC at an average purchase price of $341.83, representing about 1.92% of Zcash’s circulating supply; the ZEC treasury was valued at $129.4 million on June 30, 2026, versus cash of $7.6 million. Research and development expense fell to $0.2 million from $10.5 million due to completed trials and a prior workforce reduction, while general and administrative expense rose to $4.5 million from $1.8 million on higher stock-based compensation and payroll.
Subsidiary Leap Therapeutics published Phase 2 DeFianCe data for sirexatamab in metastatic colorectal cancer, reached FDA alignment on a registrational Phase 3 trial in DKK1-high second-line patients, and received Fast Track designation. Leap also began a strategic process to secure financing or a potential transaction to advance sirexatamab into Phase 3.
Cypherpunk Technologies (Nasdaq: CYPH), via its oncology subsidiary Leap Therapeutics, reported peer-reviewed Phase 2 DeFianCe results of sirexatamab (DKN-01) in second-line metastatic colorectal cancer in Clinical Cancer Research.
The randomized Part B enrolled 188 patients to sirexatamab plus FOLFIRI or mFOLFOX6 and bevacizumab versus chemotherapy and bevacizumab alone. Analyses showed that baseline plasma DKK1 is a continuous biomarker, with sirexatamab benefit increasing as DKK1 levels rise. In DKK1-high patients above the median (n=88), objective response rate was 38.0% versus 23.7%, median PFS 9.0 vs 7.1 months (HR 0.61), and overall survival not reached vs 14.4 months (HR 0.42). In the upper DKK1 quartile (n=44), ORR was 44.0% vs 15.8%, PFS 9.4 vs 5.9 months (HR 0.46), and OS not reached vs 9.5 months (HR 0.17).
The prespecified primary PFS endpoint in the intent-to-treat population was not met (HR 0.84). Safety was generally comparable between arms, with grade ≥3 adverse events in 59.3% vs 67.0%. According to the company, these data support a biomarker-selected Phase 3 trial and follow the May 2026 FDA Fast Track designation for sirexatamab in DKK1-high mCRC.
Cypherpunk Technologies (Nasdaq: CYPH) reported a Q1 2026 net loss of $77.2 million, largely driven by a $77.6 million unrealized loss as Zcash (ZEC) fell from $508.09 to $240.47.
The company increased its Zcash treasury to 314,185.70 ZEC (about 1.88% of circulating supply) and invested $5 million in Zcash Open Development Labs. Subsidiary Leap Therapeutics reported positive Phase 2 DeFianCe colorectal cancer data and received FDA Fast Track designation for sirexatamab.
Cypherpunk (Nasdaq: CYPH) purchased 9,163.32 ZEC for $2,150,000 at an average of $234.63 per ZEC, bringing total ZEC holdings to 303,906.40 ZEC at an average cost of $332.83 and representing 1.82% of the Zcash network.
The company also launched a new website and investor dashboard at cypherpunk.com and said future ZEC acquisition announcements and updates will be posted via its digital channels, social media, and SEC filings.
Cypherpunk (Nasdaq: CYPH) reported full‑year 2025 results and strategic shifts. Key highlights include a $58.88 million private placement, acquisition of 294,743.10 ZEC (~1.78% of circulating supply) at an average $335.89, a $5 million investment in ZODL, and a return to $4.8 million net income driven by a $50.4 million unrealized gain on ZEC. Leap Therapeutics presented positive Phase 2 sirexatamab data in DKK1‑high colorectal cancer. Cash totaled $14.0 million and ZEC holdings were valued at $147.4 million at year‑end.
Cypherpunk (Nasdaq: CYPH) invested $5M in Zcash Open Development Lab (ZODL) on March 9, 2026, marking its first technology investment beyond ZEC. ZODL, led by former ECC CEO Josh Swihart, houses the Zashi wallet tech (now Zodl) that helped grow Orchard shielded pool from ~1M to ~4M ZEC in 2025.
Cypherpunk holds 294,743.10 ZEC at an average cost of $335.89, representing ~1.78% of the network; the investment is positioned to expand wallet and protocol-level adoption for Zcash.
Cypherpunk Technologies (Nasdaq: CYPH) appointed Arjun Khemani as a Strategic Advisor on Jan 22, 2026 to advise on Zcash ecosystem dynamics and long-term privacy strategy. The hire follows recent advisor additions including Zooko Wilcox and Josh Swihart and aims to support adoption of privacy-preserving infrastructure.
Corporate treasury update: as of Dec 30, 2025 Cypherpunk holds 290,062.67 ZEC at an average acquisition price of $334.41 per ZEC, representing an estimated 1.76% of circulating Zcash supply. The position originated from a $58.88 million private placement led by Winklevoss Capital.
Cypherpunk Technologies (Nasdaq: CYPH) announced an expanded corporate treasury position in Zcash, acquiring an additional 56,418.09 ZEC for approximately $29 million at an average price of $514.02 per ZEC. After this purchase, the company's total ZEC holdings total 290,062.67 ZEC, acquired at a cumulative average price of $334.41 per ZEC, representing an estimated 1.76% of circulating supply.
The company reiterated a target to accumulate 5% of the Zcash network and said it will continue work on privacy-preserving technologies while executing its Zcash strategy.
Cypherpunk Technologies (Nasdaq: CYPH) named Josh Swihart, CEO of Electric Coin Company, as a Strategic Advisor on Dec 19, 2025 to guide Zcash ecosystem and protocol-level strategy. The appointment follows a November rebrand and a $58.88 million private placement led by Winklevoss Capital.
As of Nov 17, 2025 Cypherpunk deployed approximately $68 million to acquire 233,644.56 ZEC (about 1.43% of Zcash supply) and added advisors including Zcash founder Zooko Wilcox.